Tislelizumab,Sorafenib
BeiGene,bayer,novartis
['tislelizumab', 'beigene']
beigene announces data presentations at esmo 2022 including late-breaking oral presentation for tislelizumab in first-line unresectable hepatocellular cancer 
The Headlines of Today is a World News Website, Provide World News, International Breaking News, Tech , spots and entertainment News